Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy. The present invention further provides methods for the rational selection of therapy with one or more anticancer drugs tailored to target signal transduction pathway components with dysregulated expression and/or activation levels in patients with somatic mutations in an oncogene.
1. A method for selecting an anticancer drug targeting cMET and/or IGF1R to administer to a subject with colorectal cancer (CRC) and having a cancer cell with a KRAS mutation, the method comprising:
(a) lysing a cancer cell with a KRAS mutation isolated from the subject with CRC to produce a cellular extract;
(b) detecting the expression level and/or activation level of cMET and/or the expression level of IGF1R in the cellular extract using a Collaborative Enzyme Enhanced Reactive ImmunoAssay;
(c) calculating a statistically significant higher expression level and/or activation level of cMET and/or a statistically significant higher expression level of IGF1R from step (b) compared to an expression level and/or activation level of cMET and/or an expression level of IGF1R in a cellular extract from a cancer cell with wild-type KRAS isolated from a subject with CRC; and
(d) administering the anticancer drug targeting cMET and/or IGF1R to the subject with CRC and having the cancer cell with the KRAS mutation.
2. The method of claim 1 , further comprising detecting the expression level and/or activation level of one or more FGFRs, VEGFRs, or combinations thereof.
3. The method of claim 1 , wherein the expression level of cMET or the expression level of IGF1R is higher in the cellular extract obtained from the cancer cell with the KRAS mutation compared to the cellular extract from the cancer cell with wild-type KRAS.
4. The method of claim 1 , wherein the activation level of cMET is higher in the cellular extract obtained from the cancer cell with the KRAS mutation compared to the cellular extract obtained from the cancer cell with wild-type KRAS.
5. The method of claim 1 , wherein the KRAS mutation is selected from the group consisting of G12S, G12D, G12A, G12V, G12R, G12C, G13D, and combinations thereof.
6. The method of claim 1 , wherein the cancer cell is a circulating tumor cell (CTC) or a fine needle aspirate (FNA) cell obtained from a colorectal tumor.
7. The method of claim 6 , wherein the tumor is primary tumor tissue or metastatic tumor tissue.
8. The method of claim 1 , further comprising detecting the expression level and/or activation level of one or more ErbB RTKs.
9. The method of claim 8 , wherein the expression level and/or activation level of the one or more ErbB RTKs is higher in the cellular extract obtained from the cancer cell with the KRAS mutation as compared to a reference expression level and/or activation level of the same ErbB RTKs.
10. The method of claim 9 , further comprising determining that an anticancer drug targeting one or more ErbB RTKs should be administered to the subject having the cancer cell with the KRAS mutation.
11. The method of claim 8 , wherein the one or more ErbB RTKs is selected from the group consisting of HER1, HER2, HER3, HER4, and combinations thereof.
12. The method of claim 1 , wherein the anticancer drug targeting cMET and/or IGF1R is selected from the group consisting of a monoclonal antibody, a tyrosine kinase inhibitor, an anti-proliferative agent, a chemotherapeutic agent, and combinations thereof.
13. The method of claim 1 , wherein the expression level and activation level of cMET are higher in the cellular extract obtained from the cancer cell with the KRAS mutation compared to the cellular extract obtained from the cancer cell with wild-type KRAS.
14. The method of claim 1 , wherein the expression level of cMET and the expression level of IGF1R are higher in the cellular extract obtained from the cancer cell with the KRAS mutation compared to the cellular extract obtained from the cancer cell with wild-type KRAS.
15. The method of claim 1 , wherein the activation level of cMET and the expression level of IGF1R are higher in the cellular extract obtained from the cancer cell with the KRAS mutation compared to the cellular extract obtained from the cancer cell with wild-type KRAS.
16. The method of claim 1 , wherein the expression level and activation level of cMET and the expression level of IGF1R are higher in the cellular extract obtained from the cancer cell with the KRAS mutation compared to the cellular extract obtained from the cancer cell with wild-type KRAS.
17. The method of claim 10 , wherein the anticancer drug targeting one or more ErbB RTKs is selected from the group consisting of a monoclonal antibody, a tyrosine kinase inhibitor, an anti-proliferative agent, a chemotherapeutic agent, and combinations thereof.